npj Vaccines (Aug 2022)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

  • Johannes B. Goll,
  • Aarti Jain,
  • Travis L. Jensen,
  • Rafael Assis,
  • Rie Nakajima,
  • Algis Jasinskas,
  • Lynda Coughlan,
  • Sami R. Cherikh,
  • Casey E. Gelber,
  • S. Khan,
  • D. Huw Davies,
  • Philip Meade,
  • Daniel Stadlbauer,
  • Shirin Strohmeier,
  • Florian Krammer,
  • Wilbur H. Chen,
  • Philip L. Felgner

DOI
https://doi.org/10.1038/s41541-022-00524-7
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.